



an Open Access Journal by MDPI

## Recent Advances in Psychopharmacology

Guest Editors:

### Prof. Dr. Roos Van Westrhenen

1. Parnassia Psychiatric Institute, Amsterdam, The Netherlands
2. Institute of Psychiatry, Psychology and Neuroscience (IoPPN) Kings College, London, UK
3. Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands
4. St. John's National Academy of Health Sciences, Bangalore, India

### Prof. Dr. Allan H. Young

1. Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
2. South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham, Kent BR3 3BX, UK

Deadline for manuscript submissions:

**closed (30 April 2024)**



[mdpi.com/si/171597](https://mdpi.com/si/171597)

### Message from the Guest Editors

Dear Colleagues,

Performing clinical trials in psychiatry is a challenge as it is difficult to include a sufficient number of patients and assess reliable outcome parameters, and due to the fact that drug companies have stopped almost all psychopharmaca discoveries. In general, the availability of new psychopharmaca to patients takes nearly nine years, and the likelihood of drug approval in psychiatry is only 6.2%. Thus, novel strategies in psychiatry are urgently needed.

Today, medication selection in psychiatry relies on a trial-and-error approach based mainly on physicians' experience. Pharmacogenetic testing can help in this process by determining the person-specific genetic factors. In this Special Issue, some exciting examples of newly registered medications in psychiatry will be described, in addition to recent pharmacogenetic advances including the start of a clinical trial implementing pharmacogenetics in people with mood, anxiety, and psychotic disorders.

Prof. Dr. Roos Van Westrhenen

Prof. Dr. Allan Young

*Guest Editors*

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)